Exelixis drug improves overall survival in liver cancer patients

Published 7y ago

Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company's shares soaring 31 percent. More »